by François Briand | Mar 3, 2024 | 2022
iLEADS BMS presents the effects of its novel FXR agonist in Physiogenex’s ALD/MetALD hamster models – check the poster content here If you are interested to evaluate your novel therapies with Physiogenex, feel free to contact us to discuss your next...
by François Briand | Jan 30, 2024 | 2022
HepaRegenix publishes data on first in class MKK4 inhibitors demonstrating benefits in Physiogenex CCl4 mouse model of liver fibrosis. Review the manuscript here. If you also wish to demonstrate the efficacy of your therapies in Physiogenex models, feel free to...
by François Briand | Dec 4, 2023 | 2022
iLeads BMS publishes a new manuscript about its novel FXR agonist in Physiogenex’s obese MASH hamster and mouse models – review the manuscript here. If you wish to evaluate your novel therapies using Physiogenex CRO services and models, feel free to...
by François Briand | Nov 23, 2023 | 2022
Physiogenex will be presenting its innovative obese MetALD hamster model at the 7th Obesity and NASH Summit in Boston, MA, USA, Nov. 27-29, 2023. This unique preclinical model will be presented during the poster session on November the 28th at 2:30pm by Dr. François...
by François Briand | Nov 6, 2023 | 2022
Physiogenex will be presenting a novel obese NASH hamster model of MetALD (Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) and Alcohol-Associated Liver Disease) at the AASLD Liver Meeting in Boston, USA, Nov. 10-14th, 2023. This unique model will be...
by François Briand | Nov 6, 2023 | 2022
Physiogenex is a proud sponsor of the Hanson Wade 7th IPF Summit to be held in Boston, Sept. 19-21, 2023: On Sept.20th, Dr. François Briand, our Director of Research and Business Development, will be presenting Bleomycin-induced IPF in diet-induced obese (DIO) mice, a...
